Skip to content
Screener

Generate Biomedicines, Inc. GENB Debt-to-equity

Debt-to-equity at other companies

Semtech logo
SemtechSMTC
0.9×-0.1×
Synopsys logo
SynopsysSNPS
0.4×-0.7×
Nucor logo
NucorNUE
0×0.0×
Northern Trust logo
Northern TrustNTRS
0×0.0×
Dycom Industries logo
Dycom IndustriesDY
1.6×+0.7×
Berkshire Hathaway logo
Berkshire HathawayBRK.A
0×0.0×

Other financials

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
Net income-$67.3M-28.3%
EPS (diluted)-$0.52+73.2%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation

See full
Market cap$1.86B+19.8%
Enterprise value$1.78B—
P/S57.2×—

Profitability

See full
Operating margin-751.2%—
Net margin-685.9%—
FCF margin-756.9%—

Returns & leverage

See full
Return on equity2,979.4%—
Current ratio8.3×—

Where this comes from

Calculated from Generate Biomedicines, Inc.’s reported figures.

total debt/total stockholders equity=0.1×

Based on the most recent quarter.

The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336437

FAQ

What is Generate Biomedicines, Inc.'s debt-to-equity?
Generate Biomedicines, Inc. (GENB) reported debt-to-equity of 0.1× in Q2 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Generate Biomedicines, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude